Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 118

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 118
---
 any such variance could cause a significant fluctuation in operating results from one period to the next.

In addition, our measures
compensation cost for stock-based awards made to employees, directors and non-employee consultants based on the fair value of the award
on the grant date and we recognize the cost as an expense over the requisite service period, as applicable. Because the variables that
we uses as a basis for valuing stock-based awards change over time, including our underlying stock price and stock price volatility,
the magnitude of the expense that we must recognize may vary significantly.

Furthermore, operating results
may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including
the following:

| ● | delays in the commencement,                                               
 enrollment and the timing of clinical testing for our product candidates; |

| ● | the timing and success                                                                                                           
 or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive 
 landscape of our industry, including consolidation among our competitors or partners;                                            |

| ● | any delays in regulatory                                           
 review and approval of product candidates in clinical development; |

| ● | the timing and cost of,                                                                                            
 and level of investment in, R&D activities relating to our product candidates, which may change from time to time; |

| ● | the cost of manufacturing                                                                                            
 our product candidates, which may vary depending on FDA guidelines and requirements, and the quantity of production; |

| ● | Our ability to obtain additional       
 funding to develop product candidates; |

| ● | expenditures that our will                                                         
 or may incur to acquire or develop additional product candidates and technologies; |

| ● | the level of demand for                                                             
 our product candidates, should they receive approval, which may vary significantly; |

| ● | potential side effects                                                                                                        
 of our product candidates that could delay or prevent commercialization or cause an approved drug to be taken off the market; |

| ● | the ability of patients                                                                                            
 or healthcare providers to obtain coverage of or sufficient reimbursement for our product candidates, if approved; |

<div align='center'>61</div>

| ● | Our dependency on third-party                                  
 manufacturers to supply or manufacture our product candidates; |

| ● | Our ability to establish                                                          
 an effective sales, marketing and distribution infrastructure in a timely manner; |

| ● | market acceptance of our                                                                          
 product candidates, if approved, and our ability to forecast demand for those product candidates; |

| ● |